Zhunpeng Shu

Prof. Zhunpeng Shu

Guangdong Pharmaceutical University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Pharmacological Research
Verified
Journal Article
Closed access
ZDZihe Ding
Zihe Ding
RZRenxing Zhong
Renxing Zhong
YYYanni Yang
Yanni Yang
TXTianyi Xia
Tianyi Xia
WWWujing Wang
Wujing Wang
ZSZhunpeng Shu
Zhunpeng Shu

1 February 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZDZihe Ding
Zihe Ding
RZRenxing Zhong
Renxing Zhong
TXTianyi Xia
Tianyi Xia
YYYanni Yang
Yanni Yang
NXNa Xing
Na Xing
ZSZhunpeng Shu
Zhunpeng Shu
Acute lung injury (ALI) is a common and serious disease. Numerous treatment options are available but they do not improve quality of life or reduce mortality for ALI patients. Here, we review the treatments for ALI to provide basic data for ALI drug therapy research and development. Chinese Materia Medica (CMM) has long been the traditional clinical approach in China for the treatment of ALI and it has proven efficacy. The continued study of CMM has disclosed new potential therapeutic ingredients for ALI. However, few reviews summarize the currently available CMM-based anti-ALI drugs. Therefore, the systematic analysis of research progress in anti-ALI CMM is of great academic and clinical value. The aim of the present review is to describe CMM-based research progress in ALI treatment. Data were compiled by electronic retrieval (CNKI, SciFinder, PubMeds, Google Scholar, Web of Science) and from articles, patents and ethnopharmacological literature in university libraries were systematically studied. This review introduces progress in research on the etiology and mechanisms of ALI, the anti-ALI theory and modes of action in traditional Chinese medicine (TCM), anti-ALI active constituents of CMM, research progress in experimental methods of CMM anti-ALI, the anti-ALI molecular mechanisms of CMM, the anti-ALI efficacy of CMM formulae, and the potential toxicity of CMM and the antidotes for it. Scholars have investigated the anti-ALI molecular mechanism of CMM from various direction and have made substantial progress. This research explored the above aspects, enriched the anti-ALI theory of CMM and established the clinical significance and developmental prospects of ALI treatment by CMM. Because of the high frequency of drugs such as glucocorticoids or antibiotics, Western medicine lacks the advantages of CMM in terms of overall anti-ALI efficacy. In the future, the development of CMM-based anti-ALI therapies will become a major trend in the field of ALI drug development. Successful clinical safety and efficacy validations will promote and encourage the use of CMM. It provides fundamental theoretical support for the discovery and use of CMM resources through the comprehensive analysis of various anti-ALI CMM report databases.

8 December 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
HZHan Zhang
Han Zhang
YYYimin Yue
Yimin Yue
QZQian Zhang
Qian Zhang
LLLanyuan Liang
Lanyuan Liang
CLChuanqiu Li
Chuanqiu Li
ZSZhunpeng Shu
Zhunpeng Shu

20 September 2022 in Phytomedicine
Verified
Journal Article
Closed access
YCYing Chen
Ying Chen
MPMingming Peng
Mingming Peng
WLWei Li
Wei Li
MZMantong Zhao
Mantong Zhao
XCXia Cao
Xia Cao
ZSZhunpeng Shu
Zhunpeng Shu

17 May 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
TZTong Zhou
Tong Zhou
CZChongyang Zhang
Chongyang Zhang
XWXiao Wang
Xiao Wang
JLJiazi Lin
Jiazi Lin
JYJiamin Yu
Jiamin Yu
ZSZhunpeng Shu
Zhunpeng Shu

27 March 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YYYanni Yang
Yanni Yang
ZDZihe Ding
Zihe Ding
YWYi Wang
Yi Wang
RZRenxing Zhong
Renxing Zhong
YFYanlin Feng
Yanlin Feng
ZSZhunpeng Shu
Zhunpeng Shu
Acute lung injury (ALI) is an important cause of mortality of patients with sepsis, shock, trauma, pneumonia, multiple transfusions and pancreatitis. Physalis alkekengi L. var. franchetii (Mast.) Makino (PAF) has been extensively used in Chinese folk medicine because of a good therapeutic effect in respiratory diseases. Here, an integrated approach combining network pharmacology, proton nuclear magnetic resonance‐based metabolomics, histopathological analysis and biochemical assays was used to elucidate the mechanism of PAF against ALI induced by lipopolysaccharide (LPS) in a mouse model. We found that the compounds present in PAF interact with 32 targets to effectively improve the damage in the lung undergoing ALI. We predicted the putative signalling pathway involved by using the network pharmacology and then used the orthogonal signal correction partial least‐squares discriminant analysis to analyse the disturbances in the serum metabolome in mouse. We also used ELISA, RT‐qPCR, Western blotting, immunohistochemistry and TUNEL assay to confirm the potential signalling pathways involved. We found that PAF reduced the release of cytokines, such as TNF‐α, and the accumulation of oxidation products; decreased the levels of NF‐κB, p‐p38, ERK, JNK, p53, caspase‐3 and COX‐2; and enhanced the translocation of Nrf2 from the cytoplasm to the nucleus. Collectively, PAF significantly reduced oxidative stress injury and inflammation, at the same time correcting the energy metabolism imbalance caused by ALI, increasing the amount of antioxidant‐related metabolites and reducing the apoptosis of lung cells. These observations suggest that PAF may be an effective candidate preparation alleviating ALI.